Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea’s KHIDI, AstraZeneca Ink MOU For Oncology Research

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca inks a memorandum of understanding with Korea’s Health Industry Development Institute for oncology research.

You may also be interested in...

Deals With Pfizer, Sanofi-Aventis, AstraZeneca Boost Korea As Clinical Trial Destination

SEOUL - A string of deals during the past five years with five multinational companies - Pfizer, Sanofi-Aventis, AstraZeneca, Novartis and Japan's Otsuka Pharmaceuticals - have boosted South Korea's status as a leading destination for global clinical trials, according to the government

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.

Endo Brings All Xiaflex Revenue In House With BioSpecifics Acquisition

Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts